Abstract
The aim of the present investigation was to compare the efficacy and safety of oral ferrous asparto glycinate and ferrous ascorbate in pregnant women with iron deficiency anaemia (IDA). We performed a double blind, prospective, randomised, multicentre, parallel group comparative clinical study at three different centres in India. A total of 73 pregnant women at 12–26 weeks’ gestation were divided into two arms. While one group received ferrous ascorbate, another group was treated with ferrous asparto glycinate for a period of 28 days. The mean rise in haemoglobin and ferritin levels on day 14 and 28 was evaluated. At both time points, significantly higher levels of haemoglobin and ferritin were noticed with ferrous asparto glycinate treatment as compared with ferrous ascorbate. Our results showed that ferrous asparto glycinate is an effective iron–amino acid chelate in the management of IDA in pregnant women as compared with ferrous ascorbate. Nevertheless, additional large scale prospective, randomised trials are warranted to confirm the findings of the present efficacy trial, and also to find out the anaemia eradication rate.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
